Is a sale or reverse merger in the works? The company has one other product in clinical trials for various cancers but the same compound failed trials in other indications so I feel like they are grabbing for straws at this point on the clinical front. What they do have is over $48 million in cash as of the end of Q32014, a Net Operating Loss of $168 million, and a market cap of under $13 million. Between the recent senior leadership exits and the lack of a pipeline, I could see someone buying them for their NOL and/or early pipeline or a private company performing a reverse merger to obtain a Nasdaq listing and liquidity.
I've picked up around 60,000 shares since the recent trial failure in hopes for a quick sale.